Telesis Bio

Telesis Bio Debt / Assets

The Debt-to-Assets Ratio of Telesis Bio (TBIO) as of Oct 17, 2026 is 0.49. In the previous year, Debt-to-Assets Ratio was 0.26 — a change of 85.41% (higher).

Debt / Assets

0.49

YoY

85.41%

Last updated:

Debt-to-Assets Ratio of Telesis Bio is 2023 0.49 . Debt-to-Assets Ratio of Telesis Bio was 2022 0.26 . It decreases by 85.41% higher compared to the previous year.

The Telesis Bio Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2019
0.12 USD
Jan 1, 2020
0.31 USD
Jan 1, 2021
0.15 USD
Jan 1, 2022
0.26 USD
Jan 1, 2023
0.49 USD
The Telesis Bio Debt / Assets history
YEARDebt / AssetsYoY
0.49+85.41%
0.26+76.75%
0.15-51.93%
0.31+151.97%
0.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telesis Bio Stock analysis

What does Telesis Bio do? Telesis Bio Inc, trading under the ticker TBIO with ISIN US1920032000, is a U.S.-based company headquartered in San Diego. It operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company has 212 employees and completed its initial public offering on June 18, 2021. Telesis Bio Inc's website is https://codexdna.com/. The company focuses on research and development of genomic tools for biomedical and industrial applications. Its synthetic biology solutions aim to address challenges in the multi-step process of constructing DNA and mRNA, overcoming limitations that hinder scalable production. The BioXp system, an end-to-end automated workstation, is a key product offering. The company provides BioXp systems, including the BioXp 3250 model, along with BioXp kits for generating synthetic DNA and mRNA, and benchtop reagents designed to support automated synthetic biology workflows. Additional products include eight BioXp kits, three benchtop reagent kits, and various synthetic biology solutions such as 14 SARS-CoV-2 full-length genomes and RNA controls. The company has deployed approximately 200 BioXp systems globally. Telesis Bio Inc is engaged in developing tools that enhance the efficiency and scalability of genomic research and applications. Telesis Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telesis Bio stock

Debt-to-Assets Ratio of Telesis Bio is 0.49 in 2023.

Debt-to-Assets Ratio of Telesis Bio changed from 0.26 to 0.49, representing a 85.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Telesis Bio since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Telesis Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Telesis Bio

All Key Metrics — Telesis Bio